Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: A systematic review

Bortezomib, thalidomide, and dexamethaso

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma : A retrospective study

✍ Jonathan L. Kaufman; Ajay Nooka; Mark Vrana; Charise Gleason; L. Thompson Heffne 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract ## BACKGROUND: This single‐center retrospective study determined the efficacy of bortezomib, thalidomide, and dexamethasone (BTD) as induction for patients with multiple myeloma (MM) who were eligible for autologous stem cell transplantation (ASCT). ## METHODS: Patients with symptoma